SPONSORED CONTENT by Jerry Buller
The challenges that ‘white bagging’ poses for patients and providers are gaining attention as more health plans mandate these policies. ‘White bagging’ disrupts traditional ‘buy-and-bill’ practices for provider-administered drugs, creating patient safety concerns, operational problems, and financial challenges for covered entities.
In the traditional ‘buy-and-bill’ model, covered entities maintain control of the drug
…
The Biden administration said today it proposes to continue a nearly 30% reduction in Medicare Part B reimbursement for hospitals’ 340B-purchased drugs.
The Trump administration implemented the payment reduction in January 2018. Hospital groups say it costs affected 340B hospitals
…
In addition to weighing in on the ongoing 340B contract pharmacy standoff (see related story), the U.S. House Appropriations Committee has entered the thicket of the highly controversial topics of 340B patient definition and provider eligibility.
In its report
…
The law firm representing United Therapeutics (UT) in its 340B contract pharmacy lawsuit against the federal government has filed its own related lawsuit against the government.
In a July 13 complaint filed in federal district court in Washington, D.C.,
…
